Gene Editing and Recombinant DNA Technology

Biotechnology has emerged as a frontline pillar in India’s quest for a Viksit Bharat by 2047. For a UPSC aspirant, understanding the transition from “cutting and pasting” DNA to “precisely editing” the genetic code is vital. This article deconstructs the science, applications, and regulatory hurdles of Recombinant DNA (rDNA) and Gene Editing.

Recombinant DNA (rDNA) Technology: The Foundation

Recombinant DNA technology, often called Genetic Engineering, involves joining DNA molecules from two different species and inserting them into a host organism to produce new genetic combinations.

The Technical Workflow

• Isolation: Extracting DNA from the donor organism.
• Fragmentation: Using Restriction Endonucleases (Molecular Scissors) to cut DNA at specific palindromic sequences.
• Ligation: The desired gene is joined with a Vector (like a Plasmid) using DNA Ligase (Molecular Glue).
• Transformation: The recombinant DNA is introduced into a host cell (e.g., E. coli).
• Selection: Identifying the transformed cells using Selectable Markers (like antibiotic resistance).

The Next Frontier: Gene Editing & CRISPR-Cas9

While rDNA technology adds an entire foreign gene, Gene Editing allows for the precise addition, removal, or alteration of specific DNA sequences within the organism’s own genome.

CRISPR-Cas9: The Molecular GPS

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) uses a guide RNA to find a specific spot in the DNA. The Cas9 enzyme then acts as a scalpel to cut the DNA. This is far more precise, cheaper, and faster than traditional rDNA techniques.

Strategic Applications in India

A. Agriculture: Beyond Bt Cotton

India is moving toward Climate-Resilient Agriculture. While rDNA gave us Bt Cotton, gene editing is now being used to develop:

• Biofortified Crops: Enhancing nutritional value (e.g., Golden Rice).
• Abiotic Stress Tolerance: Crops that survive drought, salinity, and heat—crucial for India’s changing climate.
• Regulatory Update: The Ministry of Environment has exempted SDN-1 and SDN-2 (Site-Directed Nucleases) category gene-edited plants from the stringent biosafety regulations applied to traditional GMOs.

B. Healthcare: The Era of Precision Medicine

• Gene Therapy: Treating genetic disorders like Thalassemia and Sickle Cell Anaemia, which have a high burden in India’s tribal populations.
• DNA Vaccines: India’s ZyCoV-D became the world’s first plasmid DNA vaccine for COVID-19, showcasing our indigenous rDNA capabilities.

The Regulatory Framework in India

Biotechnology is governed by a multi-tiered system under the 1986 Environment Protection Act:

1. GEAC (Genetic Engineering Appraisal Committee): The apex body under the MoEFCC that approves the commercial release of GMs.
2. RCGM (Review Committee on Genetic Manipulation): Functions under the Department of Biotechnology (DBT) for research-level approvals.
3. BioE3 Policy: The government’s recent push for High-Performance Biomanufacturing, focusing on “Economy, Employment, and Environment.”

Ethical and Security Concerns

• Off-target mutations: Unintended changes in the genome.
• Germline Editing: Changes that can be inherited by future generations, raising the “Designer Baby” debate.
• Biosecurity: The risk of creating “dual-use” pathogens.

Previous Year Questions (PYQs) & Practice

Prelims Focus (MCQ)

Q. With reference to ‘CRISPR-Cas9’ technology, which of the following statements is correct? (2020)

(a) It is a gene-editing tool.

(b) It is a molecular tool for the synthesis of artificial proteins.

(c) It is a method of detecting viral infections in the blood.

(d) It is a technique used in DNA profiling.

Answer: (a)

Mains Focus

Q1. (2023) “What is the basic principle behind vaccine development? How do vaccines work? What contribution has Indian vaccine manufacturers made as part of the mandate to fight the COVID-19 pandemic?” (15 Marks, 250 Words)

The Principle of Vaccine Development is rooted in Biomimicry and the Adaptive Immune System. It involves introducing an Antigen—a weakened, killed, or structural part of a pathogen—into the body to stimulate a protective response without causing the actual disease.

How Vaccines Work

1. Antigen Presentation: When the vaccine enters the bloodstream, Antigen-Presenting Cells (APCs) digest the antigen and display it to T-lymphocytes.
2. Activation: This triggers B-lymphocytes to produce specific proteins called Antibodies that neutralize the pathogen.
3. Immunological Memory: The body produces Memory B and T cells. If the individual is exposed to the actual pathogen in the future, these memory cells recognize it instantly, launching a rapid and massive antibody response to eliminate the threat before illness occurs.

Contribution of Indian Manufacturers (COVID-19)

India emerged as a global leader, fulfilling its role as the “Pharmacy of the World”:

• Indigenous R&D: Bharat Biotech developed Covaxin, an inactivated-virus vaccine, showcasing India’s high-end biosafety (BSL-3) research.
• Mass Production: The Serum Institute of India (SII) manufactured Covishield, providing billions of doses globally.
• Technological Milestones: India produced the world’s first DNA-based vaccine (ZyCoV-D) and the first intranasal vaccine (iNCOVACC).
• Vaccine Maitri: India supplied over 200 million doses to 100+ countries, ensuring global health equity and strengthening diplomatic ties through humanitarian assistance.

This effort not only secured India’s 1.4 billion people but also bridged the global “vaccine divide,” proving India’s strategic importance in the global biotechnology landscape.

Q2. (Practice Question) “Critically analyze the potential of gene-editing technology in achieving the goal of ‘Zero Hunger’ in India. Discuss the regulatory challenges associated with the commercialization of gene-edited crops.” (15 Marks, 250 Words)

The goal of ‘Zero Hunger’ (SDG 2) requires India to ensure food availability, accessibility, and nutritional security for 1.4 billion people. Gene-editing technologies, particularly CRISPR-Cas9, offer a precise, faster, and more cost-effective alternative to traditional transgenic (GMO) methods to achieve this.

Potential in Achieving ‘Zero Hunger’

1. Climate Resilience: Gene editing can develop “climate-smart” crops resistant to abiotic stresses like salinity, drought, and heatwaves—critical for India’s rain-fed agriculture.
2. Biofortification: It enables the enhancement of micro-nutrients in staples (e.g., Zinc-enriched rice or High-Protein maize), addressing the “hidden hunger” prevalent in India.
3. Reducing Yield Gaps: By modifying genes responsible for plant architecture and pest resistance (e.g., blast-resistant rice), it minimizes harvest losses.
4. Post-Harvest Security: Editing genes to delay ripening (e.g., in tomatoes) can significantly reduce food wastage in India’s fragmented cold chains.

Regulatory Challenges

Despite the potential, commercialization faces several hurdles:

1. Regulatory Complexity: Although the government exempted SDN-1 and SDN-2 categories from the stringent Rules of 1989, clear, long-term protocols for field trials and commercial release remain evolving.
2. Public Perception and Trust: The “anti-GMO” sentiment often spills over to gene editing. Differentiating “Gene-Edited” (no foreign DNA) from “Genetically Modified” (transgenic) in the public eye is a major challenge.
3. Intellectual Property Rights (IPR): High licensing costs of CRISPR technology may lead to corporate monopolies, potentially making seeds unaffordable for small and marginal farmers.
4. Traceability and Labeling: Establishing robust laboratory infrastructure to distinguish gene-edited produce from natural variants is essential for international trade and consumer choice.

Gene editing is a potent tool for India’s Second Green Revolution. However, its success depends on a science-based regulatory framework, public-private partnerships, and an inclusive approach that ensures technology reaches the last-mile farmer.